Abstract

FORMULATION AND EVALUATION OF MONTELUKAST SODIUM ORO DISPERSIBLE TABLETS

Nagineni Sudarshan Rao* and Padira Priyanka

.

Abstract

The main aim of the present study is to design and develop oro dispersible tablets of Montelukast sodium. Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. Montelukast is also used to prevent exerciseinduced bronchoconstriction (EIB), and treat symptoms of seasonal (short-term) or perennial (long-term) allergies, such as sneezing, runny nose, itching, or wheezing. Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1, receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD4 at the CysLT1, receptor without any agonist activity. Montelukast sodium is prepared by using sublimation method. Croscarmellosesodium(S1-S3), Sodium starch glycolate(S4-S6), and Cross povidone(S5-S9) are used as super disintegrants. The formulation which contain crosscarmellose sodium exhibits rapid disintegration time, when compared with other disintegrants. But the formulation S9 which contain crosspovidone as super disintegrant has shown the maximum drug release with time, when compared with other super disintegrants. the order of selection of super disintegrents is cross povidone>cross carmellose sodium>sodium starch glycolate.

Keywords: Oro dispersible tablets, Montelukast sodium, Croscarmellose sodium, sodium starch glycolate, crospovidone.